TMS vs ECT: Comparing Two Brain Stimulation Treatments for Depression

TMS vs ECT: Comparing Two Brain Stimulation Treatments for Depression

In the TMS vs ECT choice for depression, electroconvulsive therapy (ECT) works faster and produces more remissions in the most severe cases, while transcranial magnetic stimulation (TMS) needs no anesthesia and does not cause the memory loss that ECT can. A 2014 meta-analysis of 9 head-to-head trials by Ren and colleagues found response rates of 64.4% with ECT versus 48.7% with high-frequency rTMS, a gap that was largest in psychotic depression and small in non-psychotic depression.

When antidepressants and therapy have not produced adequate relief, brain stimulation becomes part of the conversation. Two treatments dominate this space: transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT). Both are FDA-cleared, both have strong evidence behind them, and both fill a real gap in depression treatment for the roughly one-third of patients who do not respond adequately to medication.

TMS and ECT are very different treatments in how they work, what a session is like, the side effects they carry, and who qualifies for each. Those differences, more than headline response rates, usually decide which one a psychiatrist recommends first, and they are laid out below in the order most people weigh them.

What is the difference between TMS and ECT?

TMS uses a magnetic coil on the scalp to stimulate one targeted brain region while the patient is awake, and it does not cause a seizure. ECT passes a brief electrical current through the brain under general anesthesia to trigger a controlled seizure that affects the whole brain. Both treat major depressive disorder, also called major depression or clinical depression, when medication has not been enough.

Because ECT acts on the whole brain, it tends to work faster and more often in the most severe illness, at the cost of anesthesia and possible memory effects. Because TMS acts on one circuit, it is gentler and fits around work and family life, at the cost of more visits and a somewhat lower remission rate. The table below sets the two side by side.

How Each Treatment Works

TMS: Magnetic Pulses to Targeted Brain Regions

Transcranial magnetic stimulation uses a magnetic coil placed against the scalp to deliver focused magnetic pulses to specific regions of the brain. For depression, the primary target is the left dorsolateral prefrontal cortex (DLPFC), a region consistently shown to be underactive in depressed patients. The magnetic pulses induce small electrical currents in the targeted neurons, increasing their activity and restoring function in circuits involved in mood regulation.

TMS does not require anesthesia or sedation. You sit in a chair, awake and alert, while the coil is positioned on your head. Each session lasts 3 to 40 minutes depending on the protocol used. Standard repetitive TMS (rTMS) takes about 37 minutes per session. The newer theta burst stimulation (TBS) protocol condenses the treatment into roughly 3 minutes per session with comparable efficacy, according to the THREE-D trial (Blumberger and colleagues, The Lancet, 2018). The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, which delivers multiple TBS sessions per day over five days, has shown remission rates exceeding 78% in initial studies. The theta burst stimulation explainer covers how these faster protocols differ.

A standard TMS course consists of 36 sessions delivered over six to nine weeks (five sessions per week for the first six weeks, then a taper). For more detail on the treatment process, see our TMS therapy guide.

ECT: Controlled Electrical Seizure Under Anesthesia

Electroconvulsive therapy delivers a brief, controlled electrical current through the brain to induce a generalized seizure lasting 30 to 60 seconds. The procedure is performed under general anesthesia with a muscle relaxant, so the patient is unconscious and does not physically convulse. The seizure itself is monitored via EEG and is believed to produce its therapeutic effect by triggering widespread changes in brain chemistry, including increases in BDNF (brain-derived neurotrophic factor), alterations in neurotransmitter systems, and changes in brain connectivity.

ECT has been in use since the 1930s, though modern ECT bears little resemblance to the dramatized portrayals in films. Current techniques use brief-pulse or ultra-brief-pulse stimulation, precise electrode placement (right unilateral vs. bitemporal), and careful anesthesia protocols to maximize efficacy while minimizing cognitive side effects.

A typical acute ECT course involves 6 to 12 sessions delivered two to three times per week over three to four weeks. Some patients require maintenance ECT (weekly to monthly sessions) to sustain improvement.

Efficacy: Head-to-Head Comparison

ECT holds a slight edge in overall response rates, particularly for the most severe, treatment-resistant cases. It also tends to work faster, which is why it remains the treatment of choice for psychiatric emergencies such as severe depression with active suicidality, catatonia, or psychotic depression. The SAINT protocol for TMS has shown remarkably high remission rates in initial studies, and if those results are replicated in larger trials, the efficacy gap may narrow considerably.

One important distinction: response rates depend heavily on how treatment-resistant the patient population is. In patients who have failed one or two medications, TMS performs well. In patients who have failed four or more medications, ECT tends to outperform TMS.

The ranges in the table come from different trials with different patients, so they are a guide rather than a precise score. The fairest comparison is the small group of randomized trials that assigned patients to TMS or ECT directly, which the next section summarizes.

What does the research say about TMS versus ECT?

Direct comparisons favor ECT for the sickest patients and show TMS holding its own in non-psychotic depression. Most of the head-to-head trials are small, older and used standard rTMS rather than today's theta burst or accelerated protocols, so the evidence is solid on ECT's strength and thin on how the newest TMS protocols compare.

Studies that compared TMS and ECT directly

Ren and colleagues (2014) pooled 9 randomized trials with 425 patients and found ECT superior to high-frequency rTMS for response (64.4% vs 48.7%) and remission (52.9% vs 33.6%), with similar dropout rates. The advantage was concentrated in psychotic depression; in non-psychotic depression, high-frequency rTMS was about as effective as ECT.

A 2017 network meta-analysis of 25 trials and 1,288 patients by Chen and colleagues ranked ECT as the most likely treatment to be most efficacious, but its lead over bilateral and right-sided rTMS was not statistically significant. Right prefrontal rTMS ranked as the best tolerated.

Landmark studies behind each treatment

• ECT: The UK ECT Review Group (The Lancet, 2003) found real ECT more effective than simulated ECT and than antidepressant medication in its systematic review and meta-analysis.
• TMS: The multisite sham-controlled trial by O'Reardon and colleagues (2007) supported the 2008 FDA clearance, and a naturalistic study of 307 patients by Carpenter and colleagues (2012) reported 58% response and 37% remission in routine US practice.
• Theta burst TMS: The THREE-D trial (Blumberger and colleagues, 2018) found 3-minute intermittent theta burst sessions non-inferior to 37-minute 10 Hz rTMS sessions.
• Accelerated TMS: In the 2022 double-blind trial of Stanford neuromodulation therapy (formerly SAINT), 29 participants were randomized, and the active group's depression scores fell by 52.5% at four weeks versus 11.1% with sham, according to Cole and colleagues.

What happens after an ECT course ends

Relapse after ECT is common, which shapes the real-world comparison. In Sackeim and colleagues' 2001 trial, relapse within 24 weeks was 84% on placebo, 60% on nortriptyline and 39% on nortriptyline plus lithium. The CORE trial by Kellner and colleagues (2006) found relapse of 37.1% with continuation ECT and 31.6% with continuation medication over six months, with no significant difference between the two.

Side Effects: Where the Differences Are Sharpest

This is where TMS and ECT diverge most dramatically, and for many patients, side effects are the deciding factor. TMS side effects are mostly local and short-lived, while ECT adds anesthesia risk and memory effects that can last weeks or longer.

TMS Side Effects

• Scalp discomfort or pain at the stimulation site: The most common side effect, reported by 30 to 50% of patients. Usually mild to moderate and decreasing over sessions as patients acclimate.
• Headache: Reported by about 20 to 30% of patients. Typically responds to over-the-counter pain relievers.
• Lightheadedness: Occasional and brief.
• Facial twitching: During treatment only, caused by magnetic pulse stimulating nearby facial muscles.
• Seizure risk: Extremely rare (less than 0.1% with standard protocols), consistent with the 2021 international safety guidelines by Rossi and colleagues. TMS is considered safe for most patients.
• No cognitive effects: TMS does not cause memory loss, confusion, or any measurable cognitive impairment in clinical trials to date.

ECT Side Effects

• Short-term memory loss: The most significant side effect. Most patients experience some degree of retrograde amnesia (difficulty recalling events from the weeks surrounding treatment) and anterograde amnesia (difficulty forming new memories during the treatment period). For the majority of patients, these effects resolve within weeks to months after completing ECT.
• Longer-term memory effects: A subset of patients (estimates vary from 10 to 30%) report persistent memory difficulties that extend beyond the acute treatment period. This is the most controversial aspect of ECT, and researchers continue to work on protocols that minimize cognitive risk. Right unilateral electrode placement with ultra-brief pulse width causes less memory disruption than bitemporal placement.
• Confusion: Post-treatment confusion is common immediately after waking from anesthesia and usually clears within an hour.
• Headache, muscle aches, nausea: Related to anesthesia and the seizure itself. Usually manageable with medication.
• Anesthesia risks: As with any procedure requiring general anesthesia, there are small risks of adverse reactions, though serious complications are rare.

How much memory is affected depends on technique as well as on the patient. In the 347-patient community study by Sackeim and colleagues (2007), bilateral ECT and older sine wave stimulation produced more lasting cognitive effects, and older age and lower baseline cognitive function predicted larger deficits. A meta-analysis by Semkovska and McLoughlin (2010) pooled 84 studies and 2,981 patients and found measured cognitive declines mainly limited to the first three days after ECT, with pretreatment levels recovered within about two weeks. That review found no standardized tests of retrograde amnesia, so it does not settle the gaps in personal memories that some patients describe.

Who Qualifies for Each Treatment

TMS Candidacy

• Diagnosis of major depressive disorder
• Failed at least one adequate trial of antidepressant medication (most insurers require at least one failure; some require two or more)
• No metal implants in or near the head (cochlear implants, aneurysm clips, deep brain stimulators, or metallic fragments near the skull are contraindications)
• No history of seizure disorder (relative contraindication)
• No active substance abuse disorder (most clinics require stability)
• Medically stable enough to attend 30+ outpatient sessions over six to nine weeks

ECT Candidacy

• Severe, treatment-resistant depression (usually after failure of multiple medications and possibly TMS)
• Depression with psychotic features
• Catatonia
• Acute suicidality requiring rapid response
• Severe depression in pregnancy (where medication risks are a concern)
• Severe depressive episodes in bipolar disorder, which fall within the FDA's 2018 class II indication for ECT devices
• Medical clearance for general anesthesia (cardiac and pulmonary evaluation as needed)
• Willingness to accept potential cognitive side effects

Who should be cautious with ECT?

ECT has few absolute contraindications, but some conditions raise its risk enough that a psychiatrist and anesthesiologist weigh them carefully. These include a recent heart attack or unstable heart disease, a recent stroke, raised pressure inside the skull and some brain aneurysms. Older adults can still receive ECT and often respond well, though they carry a higher chance of memory effects.

Both treatments are used for depression in adults, and both are being studied for related conditions. TMS devices are also FDA-cleared for obsessive-compulsive disorder, and ECT is used for catatonia and some cases of mania. People with bipolar disorder should expect a careful screen before either option, since stimulation can occasionally trigger a switch into mania.

Treatment Protocols and Practical Differences

What a TMS session is like

The first TMS visit includes motor threshold mapping, in which the clinician finds the pulse strength that makes the thumb twitch and uses it to set the treatment dose. At later visits you sit in a reclining chair with earplugs while the coil taps against the scalp in rhythmic bursts. Most people return to work or drive home straight afterward.

What an ECT session is like

ECT usually starts with a medical workup, which may include bloodwork, an ECG and an anesthesia consultation. On treatment mornings you fast, receive a short-acting anesthetic and a muscle relaxant through an IV, and wake in a recovery area a few minutes after the seizure. Expect to spend part of the day recovering and to need a driver after each session.

Cost and Insurance

TMS costs: $6,000 to $12,000 for a full course of 36 sessions without insurance. Most major insurance plans now cover TMS for treatment-resistant depression, though prior authorization and documentation of medication failures are typically required. Out-of-pocket costs with insurance vary widely depending on your plan. Some clinics offer financing or payment plans. The breakdown of TMS therapy cost covers what drives the price and how prior authorization works.

ECT costs: $25,000 to $50,000+ for a full acute course (including anesthesia, facility fees, and physician charges). Insurance covers ECT for appropriate indications in most cases, but co-pays and deductibles can still be significant. Maintenance ECT adds ongoing costs.

From a pure cost perspective, TMS is substantially less expensive than ECT. When you factor in the lower side effect profile and outpatient convenience, it becomes clear why TMS has become the first-line brain stimulation option for most treatment-resistant depression cases, with ECT reserved for more severe or urgent situations.

These figures are broad estimates, and the price you are quoted depends on the clinic, the protocol and your plan. Accelerated TMS protocols are newer, and insurance coverage for them is less settled than for standard rTMS, so ask the clinic to confirm coverage in writing before you start.

Can you switch from TMS to ECT, or use TMS after ECT?

Yes, patients move between the two treatments, and the order usually follows severity. Many people try TMS first and are referred for ECT if a full TMS course does not bring enough relief. Others start with ECT during a crisis and later discuss TMS or medication to stay well.

The evidence on sequencing is thin. Few trials have tested TMS as maintenance after ECT, and there is no agreed protocol for it. A psychiatrist will usually look at how you responded to each treatment, how quickly symptoms return and what you can manage week to week before recommending a switch.

Making the Decision

The choice between TMS and ECT is not always straightforward, but a few general principles can guide the conversation:

• Try TMS first if your depression is treatment-resistant but not in the severe or life-threatening category. It is less invasive, has fewer side effects, and does not carry cognitive risk.
• Consider ECT if your depression is severe, involves psychotic features or catatonia, involves active suicidality, or if you have already tried TMS without adequate response.
• Factor in practical constraints: TMS requires 30+ visits to a clinic over six to nine weeks. ECT requires 6 to 12 visits but with anesthesia and recovery time at each. Consider your work schedule, transportation, and support system.
• Discuss the SAINT protocol: If access is available, the SAINT TMS protocol (five days of intensive treatment) may offer a time-efficient alternative to standard TMS with potentially higher remission rates.
• Involve your psychiatrist: A psychiatrist experienced in neuromodulation can assess your specific clinical picture and make a recommendation tailored to your severity, history, and preferences.

Both TMS and ECT have helped people recover from depressions that nothing else could touch. The fact that two effective brain stimulation options exist is genuinely good news for patients who have been stuck in treatment-resistant depression. The key is matching the right treatment to the right patient at the right time.

What are the alternatives if neither TMS nor ECT fits?

Several other treatments sit alongside TMS and ECT for depression that has not responded to medication. They differ in evidence, regulatory status and how often they are covered by insurance, so they are worth raising with a psychiatrist before or after a brain stimulation course.

• Ketamine and esketamine: Esketamine nasal spray was approved by the FDA in 2019 for treatment-resistant depression, while IV ketamine for depression is off label and usually cash pay. In the ELEKT-D trial (Anand and colleagues, NEJM, 2023), IV ketamine was non-inferior to ECT in 403 patients with non-psychotic treatment-resistant depression, with response in 55.4% versus 41.2%. The ketamine therapy treatment guide and the TMS vs ketamine comparison cover that choice.
• Vagus nerve stimulation (VNS): An implanted device approved by the FDA as an add-on for chronic, treatment-resistant depression. It acts slowly, over months rather than weeks.
• Psilocybin and other psychedelic-assisted therapy: Still investigational for depression in the US outside clinical trials. The psychedelic therapy guide explains where the research stands.
• Medication and psychotherapy changes: Augmentation with lithium, an atypical antipsychotic or a different antidepressant class, paired with structured psychotherapy, remains standard care and is often continued alongside TMS or ECT.

How do you find a TMS or ECT provider?

TMS is delivered in outpatient psychiatry practices, so most people can find it locally. ECT is delivered in hospitals and some ambulatory surgery centers, usually through a hospital psychiatry department or an academic medical center, so the usual route is a referral from your psychiatrist.

The national directory of TMS clinics lists providers by state and city, for example TMS clinics in California. Listing order on Regenerated.com is not paid ranking, Featured slots are clearly labeled and capped, and a Verified label means the clinic completed credential checks, not that it spent money. The directory is free for patients, and inclusion is not an endorsement; the guide to Featured, Verified and organic listings explains each label.

Before you book, it helps to ask a few concrete questions of any TMS or ECT program:

1. Is a board-certified psychiatrist supervising treatment and reviewing progress, and who runs each session?
2. Which protocol do you use (standard rTMS, theta burst, accelerated TMS, or for ECT, right unilateral or bilateral placement and pulse width), and why for me?
3. How will you measure response, for example with the PHQ-9 or another rating scale at set points?
4. Will you handle prior authorization, and what will I owe if insurance declines?
5. What is the plan after the acute course, including maintenance sessions or medication?

The TMS treatment guide describes protocols and safety in more depth, and the overview of depression treatment options places brain stimulation alongside medication, therapy and newer approaches.

Related Reading

• TMS Therapy: How It Works and What to Expect
• Ketamine Therapy: A Complete Guide
• Neurofeedback for Anxiety: Can Brain Training Replace Medication?
• Psilocybin Therapy: Current Research and Clinical Applications

Frequently Asked Questions

Which works better for depression, TMS or ECT?

ECT works better for the most severe depression, especially psychotic depression, catatonia and acute suicidality. Standard TMS has a response rate of 50 to 60 percent and a remission rate of 25 to 35 percent, while ECT has a response rate of 50 to 70 percent and a remission rate of 30 to 50 percent. In non-psychotic depression, a 2014 meta-analysis by Ren and colleagues found the two similar, and accelerated TMS reached about 78 percent remission in one small trial.

How much does TMS cost compared to ECT?

A full course of TMS runs about $6,000 to $12,000 without insurance, while an acute ECT course costs roughly $25,000 to $50,000 or more because it includes anesthesia, facility and physician fees. Most major insurance plans cover TMS for treatment-resistant depression after documented medication trials and prior authorization, and insurance covers ECT for appropriate indications in most cases. Maintenance sessions add to the total for either treatment.

What are the main side effects of each treatment?

TMS side effects are mostly mild: scalp discomfort in 30 to 50 percent of patients, headache in 20 to 30 percent, and seizure in less than 0.1 percent, with no memory loss found in trials. ECT's main side effect is short-term memory loss, and 10 to 30 percent of patients report persistent memory difficulties. ECT also brings post-treatment confusion that usually clears within an hour, plus the risks of general anesthesia.

How long does each treatment take to work?

ECT generally works within 1 to 2 weeks, while standard TMS typically shows results in 2 to 4 weeks and the accelerated SAINT protocol reports results in as little as 5 days. A standard TMS course is 36 sessions over six to nine weeks. An acute ECT course is 6 to 12 sessions delivered two to three times per week over three to four weeks, often followed by maintenance treatment to prevent relapse.

Who is a candidate for TMS versus ECT?

TMS suits adults with major depressive disorder who have not improved after at least one adequate antidepressant trial, have no metal implants near the head and have no active substance use disorder. ECT is generally reserved for severe, treatment-resistant depression after several medications, and for psychotic depression, catatonia or acute suicidality. ECT also requires medical clearance for general anesthesia, so heart, lung and brain conditions are reviewed first.

Are TMS and ECT FDA approved?

Both TMS and ECT devices are FDA-cleared for depression, which is a device pathway rather than drug approval. The FDA first cleared a TMS device for major depression in 2008. In December 2018 it reclassified ECT devices into class II for catatonia and for severe depressive episodes in major depression or bipolar disorder that are treatment-resistant or need a rapid response, in patients 13 and older. ECT has the largest evidence base of any depression treatment after medication.